LMR Partners’s aTyr Pharma ATYR Stock Holding History

LMR Partners’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-568,900	Closed	-$410K	–	1769
2025 Q3	$410K	Buy	+568,900	New	+$2.58M	﹤0.01%	1120

Other funds holding ATYR

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's ATYR Position: Q2 2025 in Review

LMR Partners sold out of aTyr Pharma (ATYR) in Q2 2025, closing a stake of 52,087 shares — an estimated $157K sold.

LMR Partners first reported a position in ATYR in Q1 2025 and held it in 1 quarter. The position peaked at $157K in Q1 2025. 110 funds tracked by Wall St. Rank hold ATYR as of Q2 2025.

LMR Partners reported no remaining aTyr Pharma position as of Q2 2025 after selling out during the quarter.
LMR Partners sold 52,087 aTyr Pharma shares in Q2 2025, an estimated $157K.
LMR Partners first reported a position in aTyr Pharma in Q1 2025 and held it in 1 quarter.
LMR Partners's aTyr Pharma position peaked at $157K in Q1 2025.
110 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.